<DOC>
	<DOCNO>NCT00850616</DOCNO>
	<brief_summary>A study ass general safety tolerability administration 3-dose regimen MRKAd5+6 trigene vaccine</brief_summary>
	<brief_title>Three-Dose Regimen MRKAd5+6 Trigene ( V526 ) Healthy Adults ( V526-001 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject negative test HIV , Hepatitis B , Hepatitis C within 60 day injection Subject agree use acceptable method birth control week 52 study Subject give immune globulin blood product within 30 day first dose study vaccine Subject vaccinate live virus vaccine within 30 day inactivate vaccine within 5 day first dose study vaccine Subject know suspect impaired immune function Subject participate HIV vaccine trial Female subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Preventive Vaccine</keyword>
</DOC>